$SNDX has generated 13 mentions over the past 12 months from three distinct FinTwit voices, with the first mention appearing on September 8, 2025. Adam Feuerstein (@adamfeuerstein) dominates discussion with 9 mentions, followed by Jacob Plieth (@jacobplieth) with 3 mentions and InvestmentGuru (@investmentguru_) with 1 mention. The biotech sector represents the primary category of discussion around this ticker.

Recent activity includes commentary on Syndax's clinical developments, particularly regarding Revuforj frontline acute myeloid leukemia results presented at ASH25, as well as discussion of QTc prolongation warning removal efforts. As of January 6, 2026, $SNDX appeared in broader biotech breakout discussions highlighting clinical wins and asymmetric upside potential within the sector.